GlassScriptPhysician profile
Swarna P Jayasinghe
NPI 1437176237
$5,031.58
in general payments reported to CMS, 2019-2025
36 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $96.21 · 2021: $553 · 2022: $592 · 2023: $392 · 2024: $1,028 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,786.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $696.22 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $593.30 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $462.15 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $399.00 | 2019-2025 | Camzyos, Eliquis |
| Allergan, INC. | $248.92 | 2019 | |
| Alnylam Pharmaceuticals INC. | $243.66 | 2024-2025 | Amvuttra |
| Boston Scientific Corporation | $201.13 | 2019-2022 | |
| Amgen INC. | $157.83 | 2022-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.42 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $148.80 | 2021-2025 | Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $135.00 | 2025 | Attruby |
| Viiv Healthcare Company | $123.98 | 2025 | Rukobia |
| Teva Pharmaceuticals USA, INC. | $123.35 | 2024 | Austedo Xr |
| Pfizer INC. | $122.84 | 2021-2025 | |
| Gilead Sciences, INC. | $120.07 | 2025 | Epclusa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $119.44 | 2019 | |
| Insmed, INC. | $119.27 | 2019 | |
| Cardiovascular Systems INC. | $111.46 | 2019 | |
| Neurocrine Biosciences, INC. | $102.67 | 2025 | |
| Merck Sharp & Dohme LLC | $98.35 | 2021-2024 | Verquvo |
| Esperion Therapeutics, INC. | $74.86 | 2022-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $66.81 | 2019-2023 | Farxiga |
| Penumbra, INC. | $56.65 | 2025 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $49.05 | 2022-2024 | |
| Amarin Pharma, INC. | $43.60 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $42.42 | 2022-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.24 | 2023-2025 | Evkeeza |
| Daiichi Sankyo INC. | $32.51 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $30.40 | 2023-2024 | Inpefa |
| Preventice Services, LLC | $25.74 | 2021 | |
| Genzyme Corporation | $17.95 | 2025 | |
| Sage Therapeutics, LLC | $17.70 | 2025 | Zurzuvae |
| Harmony Biosciences LLC | $17.35 | 2023 | Wakix |
| Sanofi-Aventis U.S. LLC | $17.02 | 2024 | |
| Chiesi USA, INC. | $15.64 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.78 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swarna Jayasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.